These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3345720)

  • 1. Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro.
    Jordan VC; Koch R; Langan S; McCague R
    Endocrinology; 1988 Apr; 122(4):1449-54. PubMed ID: 3345720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.
    Jordan VC; Lieberman ME; Cormier E; Koch R; Bagley JR; Ruenitz PC
    Mol Pharmacol; 1984 Sep; 26(2):272-8. PubMed ID: 6482874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
    Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
    Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.
    Murphy CS; Langan-Fahey SM; McCague R; Jordan VC
    Mol Pharmacol; 1990 Nov; 38(5):737-43. PubMed ID: 2233701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone.
    Jordan VC; Koch R
    Endocrinology; 1989 Apr; 124(4):1717-26. PubMed ID: 2924721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure.
    Jordan VC; Lieberman ME
    Mol Pharmacol; 1984 Sep; 26(2):279-85. PubMed ID: 6541293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus.
    Campen CA; Jordan VC; Gorski J
    Endocrinology; 1985 Jun; 116(6):2327-36. PubMed ID: 3996316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geometric isomers of substituted triphenylethylenes and antiestrogen action.
    Jordan VC; Haldemann B; Allen KE
    Endocrinology; 1981 Apr; 108(4):1353-61. PubMed ID: 6781873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
    Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
    Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes.
    McCague R; Leclercq G; Jordan VC
    J Med Chem; 1988 Jul; 31(7):1285-90. PubMed ID: 3385723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
    Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of DNA damage in F344 rats induced by geometric isomers of tamoxifen and analogues.
    Brown K; Brown JE; Martin EA; Smith LL; White IN
    Chem Res Toxicol; 1998 May; 11(5):527-34. PubMed ID: 9585484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tamoxifen, tamoxifen metabolites, and nafoxidine on adenosine 3',5'-monophosphate phosphodiesterase: correlations with growth inhibitory activities but not estrogen receptor affinities.
    Fanidi A; Courion-Guichardaz C; Fayard JM; Pageaux JF; Laugier C
    Endocrinology; 1989 Sep; 125(3):1187-93. PubMed ID: 2547579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7.
    Roos W; Oeze L; Löser R; Eppenberger U
    J Natl Cancer Inst; 1983 Jul; 71(1):55-9. PubMed ID: 6575210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro.
    Lieberman ME; Jordan VC; Fritsch M; Santos MA; Gorski J
    J Biol Chem; 1983 Apr; 258(8):4734-40. PubMed ID: 6833271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers.
    Katzenellenbogen JA; Carlson KE; Katzenellenbogen BS
    J Steroid Biochem; 1985 May; 22(5):589-96. PubMed ID: 4010284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.
    Osborne CK; Jarman M; McCague R; Coronado EB; Hilsenbeck SG; Wakeling AE
    Cancer Chemother Pharmacol; 1994; 34(2):89-95. PubMed ID: 8194171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.